Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US

Abstract Symptomatic management of Parkinson’s disease (PD) is complex and many symptoms, especially non-motor symptoms, are not effectively addressed with current medications. In the US, cannabis has become more widely available for medical and recreational use, permitting those in the PD community...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Megan P. Feeney, Danny Bega, Benzi M. Kluger, A. Jon Stoessl, Christiana M. Evers, Rebeca De Leon, James C. Beck
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/5b4a51ed0a354e0aad2fd19f76e8c6a8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5b4a51ed0a354e0aad2fd19f76e8c6a8
record_format	dspace
spelling	oai:doaj.org-article:5b4a51ed0a354e0aad2fd19f76e8c6a82021-12-02T15:53:45ZWeeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US10.1038/s41531-021-00165-y2373-8057https://doaj.org/article/5b4a51ed0a354e0aad2fd19f76e8c6a82021-03-01T00:00:00Zhttps://doi.org/10.1038/s41531-021-00165-yhttps://doaj.org/toc/2373-8057Abstract Symptomatic management of Parkinson’s disease (PD) is complex and many symptoms, especially non-motor symptoms, are not effectively addressed with current medications. In the US, cannabis has become more widely available for medical and recreational use, permitting those in the PD community to try alternative means of symptom control. However, little is known about the attitudes towards, and experiences with, cannabis use among those living with PD. To address this shortcoming, we distributed an anonymous survey to 7,607 people with PD in January 2020 and received 1339 responses (17.6%). 1064 complete responses were available for analysis. Respondents represented 49 states with a mean age of 71.2 years (±8.3) and mean PD duration of 7.4 years (±6.2). About a quarter of respondents (24.5%) reported cannabis use within the previous six months. Age and gender were found to be predictors of cannabis use in this sample (Age OR = 0.95, 95% CI 0.93 to 0.97; Male OR = 1.44, 95% CI 1.03 to 2.03). Users reported learning about cannabis use from the internet/news (30.5%) and friends or other people with PD (26.0%). Cannabis users were more likely to report insufficient control of their non-motor symptoms with prescription medications than non-users (p = 0.03). Cannabis was primarily used for PD (63.6%) and was most often used to treat nonmotor symptoms of anxiety (45.5%), pain (44.0%), and sleep disorders (44.0%). However, nearly a quarter of users (23.0%) also reported they had stopped cannabis use in the previous six months, primarily due to a lack of symptom improvement (35.5%). Three quarters of respondents (75.5%) did not use cannabis, primarily because there was a lack of scientific evidence supporting efficacy (59.9%). Our results suggest that the lack of formal guidance or research evidence about cannabis for PD may in part underlie inconsistencies in both use and reported effectiveness.Megan P. FeeneyDanny BegaBenzi M. KlugerA. Jon StoesslChristiana M. EversRebeca De LeonJames C. BeckNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 7, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Megan P. Feeney Danny Bega Benzi M. Kluger A. Jon Stoessl Christiana M. Evers Rebeca De Leon James C. Beck Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US
description	Abstract Symptomatic management of Parkinson’s disease (PD) is complex and many symptoms, especially non-motor symptoms, are not effectively addressed with current medications. In the US, cannabis has become more widely available for medical and recreational use, permitting those in the PD community to try alternative means of symptom control. However, little is known about the attitudes towards, and experiences with, cannabis use among those living with PD. To address this shortcoming, we distributed an anonymous survey to 7,607 people with PD in January 2020 and received 1339 responses (17.6%). 1064 complete responses were available for analysis. Respondents represented 49 states with a mean age of 71.2 years (±8.3) and mean PD duration of 7.4 years (±6.2). About a quarter of respondents (24.5%) reported cannabis use within the previous six months. Age and gender were found to be predictors of cannabis use in this sample (Age OR = 0.95, 95% CI 0.93 to 0.97; Male OR = 1.44, 95% CI 1.03 to 2.03). Users reported learning about cannabis use from the internet/news (30.5%) and friends or other people with PD (26.0%). Cannabis users were more likely to report insufficient control of their non-motor symptoms with prescription medications than non-users (p = 0.03). Cannabis was primarily used for PD (63.6%) and was most often used to treat nonmotor symptoms of anxiety (45.5%), pain (44.0%), and sleep disorders (44.0%). However, nearly a quarter of users (23.0%) also reported they had stopped cannabis use in the previous six months, primarily due to a lack of symptom improvement (35.5%). Three quarters of respondents (75.5%) did not use cannabis, primarily because there was a lack of scientific evidence supporting efficacy (59.9%). Our results suggest that the lack of formal guidance or research evidence about cannabis for PD may in part underlie inconsistencies in both use and reported effectiveness.
format	article
author	Megan P. Feeney Danny Bega Benzi M. Kluger A. Jon Stoessl Christiana M. Evers Rebeca De Leon James C. Beck
author_facet	Megan P. Feeney Danny Bega Benzi M. Kluger A. Jon Stoessl Christiana M. Evers Rebeca De Leon James C. Beck
author_sort	Megan P. Feeney
title	Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US
title_short	Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US
title_full	Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US
title_fullStr	Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US
title_full_unstemmed	Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US
title_sort	weeding through the haze: a survey on cannabis use among people living with parkinson’s disease in the us
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5b4a51ed0a354e0aad2fd19f76e8c6a8
work_keys_str_mv	AT meganpfeeney weedingthroughthehazeasurveyoncannabisuseamongpeoplelivingwithparkinsonsdiseaseintheus AT dannybega weedingthroughthehazeasurveyoncannabisuseamongpeoplelivingwithparkinsonsdiseaseintheus AT benzimkluger weedingthroughthehazeasurveyoncannabisuseamongpeoplelivingwithparkinsonsdiseaseintheus AT ajonstoessl weedingthroughthehazeasurveyoncannabisuseamongpeoplelivingwithparkinsonsdiseaseintheus AT christianamevers weedingthroughthehazeasurveyoncannabisuseamongpeoplelivingwithparkinsonsdiseaseintheus AT rebecadeleon weedingthroughthehazeasurveyoncannabisuseamongpeoplelivingwithparkinsonsdiseaseintheus AT jamescbeck weedingthroughthehazeasurveyoncannabisuseamongpeoplelivingwithparkinsonsdiseaseintheus
_version_	1718385510908428288

Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US

Ejemplares similares